Showing 5451-5460 of 8791 results for "".
- Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitishttps://practicaldermatology.com/news/asthma-and-allergy-foundation-study-shows-high-prevalence-and-qol-impact-for-adults-with-atopic-dermatitis/2457872/The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related quality of life and mental health symptoms, such as depression and anxiety, for patients with moder
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-presents-analysis-of-siliq-phase-3-data-on-disease-related-anxiety-and-depression-in-patients-with-psoriasis/2457875/Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the
- Aqua Pharmaceuticals Supports Camp Discoveryhttps://practicaldermatology.com/news/aqua-pharmaceuticals-supports-camp-discovery/2457884/Aqua Pharmaceuticals, LLC is demonstrating its commitment to the dermatology community by supporting American Academy of Dermatology’s Camp Discovery and is making a donation up to $5,000 to support the camp
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- FDA Grants Priority Review for Genentech's Rituxan for Pemphigus Vulgarishttps://practicaldermatology.com/news/fda-grants-priority-review-for-genentechs-rituxan-for-pemphigus-vulgaris/2457883/The FDA has accepted Genentech’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). Genentech is a member of the Roche Group. <
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-jemdel-plaque-psoriasis-treatment/2457889/The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosin